This educational activity is supported by educational grants from the following companies:
Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Adjunctive and Supportive Care in Multiple Myeloma
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The University of Arizona Cancer Center
Patients with multiple myeloma are at risk for developing additional comorbidities, complications from the disease, and/or treatment-related comorbidities, such as thromboembolism, pathologic fractures, renal disease, neutropenia, or neuropathy. Advanced practitioners have a major role in overseeing supportive care and symptom management. Therefore, it is imperative that advanced practitioners have knowledge and expertise in this area. This activity addresses these issues, providing advanced practitioners with needed strategies necessary to provide the best patient outcomes.
Management of Newly Diagnosed Multiple Myeloma Patients
Relapsed or Refractory Multiple Myeloma
Management of Multiple Myeloma Patients Treated With Immunotherapy
Risk Stratification in Multiple Myeloma
How do IMIDs work?
What does an advanced practitioner need to know to create an optimal treatment regimen for the individual patient and explain the benefits and risks of the available choice to patients?
Briefly define low-risk vs high risk patient and how risk stratification influences treatment decisions.
What are the toxicities associated with the agents used for multiple myeloma?
What are some monitoring parameters for toxicities to establish?
How can I increase patient adherence to treatment regimens for multiple myeloma?
Bone Marrow Biopsy Demonstration Video